James FlynnManaging Partner at Deerfield Management
Jim is the Managing Partner of Deerfield. He joined Deerfield in 2000, focusing on pharmaceutical companies and gradually assuming broader responsibility throughout the firm. In 2004 Jim began co-managing the firm with Deerfield’s founder, Arnold Snider. Upon Arnie’s retirement in 2005, Jim assumed his current role overseeing Deerfield’s investment activities as well as the management of the firm. Since that time, the firm has expanded its investment capabilities to include private structured financings, developed additional proprietary market research instruments through the Deerfield Institute, and created the Deerfield Foundation to contribute toward the health and welfare of disadvantaged children.
Before joining Deerfield, Jim was a top ranked analyst at Furman Selz from 1996 to 2000, where he built a team to cover the pharmaceutical and medical device industries and also managed a proprietary trading account. Previously he served from 1993 to 1996 as Vice President of Corporate Development of Alpharma Inc., a pharmaceutical company, where his responsibilities included business development and strategic planning and the management of several licensing transactions. Jim began his career in healthcare investing from 1988 to 1993 at Kidder, Peabody & Co., where he ultimately served as a senior analyst covering the specialty pharmaceutical industry.
Since 2009, Jim has served as the Chairman of the Quality Committee of the Board of Trustees of Continuum Health Partners until its merger in 2013 with Mount Sinai Health System, where he continues to serve on the Board of Trustees. He also serves on the Board of Trustees of the New York Academy of Medicine. He holds a B.S. in Cellular and Molecular Biology and Economics from the University of Michigan.